Literature DB >> 23757365

MicroRNAs as therapeutic targets in chemoresistance.

Michela Garofalo1, Carlo M Croce.   

Abstract

Despite substantial progress in understanding the cancer signaling network, effective therapies remain scarce due to insufficient disruption of oncogenic pathways, drug resistance and drug-induced toxicity. New and more creative approaches are therefore required for the treatment of cancer. MicroRNAs (miRNAs) are a family of small noncoding RNAs that regulate gene expression by sequence-selective targeting of mRNAs, leading to a translational repression or mRNA degradation. Experimental evidence demonstrates that dysregulation of specific miRNAs leads to drug resistance in different cancers and correction of these miRNAs using miRNA mimics or antagomiRs can normalize the gene regulatory network and signaling pathways and sensitize cancerous cells to chemotherapy. Therefore, miRNA-based gene therapy provides an attractive anti-tumor approach for integrated cancer therapy. Here, we will discuss the involvement of microRNAs in chemotherapy resistance and focus on recent advancements in the development and delivery of miRNA-based cancer therapeutics.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Chemotherapy; Drug resistance; MicroRNA

Mesh:

Substances:

Year:  2013        PMID: 23757365      PMCID: PMC3858390          DOI: 10.1016/j.drup.2013.05.001

Source DB:  PubMed          Journal:  Drug Resist Updat        ISSN: 1368-7646            Impact factor:   18.500


  143 in total

1.  Molecular mechanisms of resistance to taxanes and therapeutic implications.

Authors:  Franco Zunino; Giuliana Cassinelli; Donatella Polizzi; Paola Perego
Journal:  Drug Resist Updat       Date:  1999-12       Impact factor: 18.500

2.  Aberrant microRNA expression in Chinese patients with chronic lymphocytic leukemia.

Authors:  Dan-Xia Zhu; Kou-Rong Miao; Cheng Fang; Lei Fan; Wei Zhu; Hua-Yuan Zhu; Yun Zhuang; Ming Hong; Peng Liu; Wei Xu; Jian-Yong Li
Journal:  Leuk Res       Date:  2010-12-03       Impact factor: 3.156

3.  Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells.

Authors:  Kammei Rai; Nagio Takigawa; Sachio Ito; Hiromi Kashihara; Eiki Ichihara; Tatsuji Yasuda; Kenji Shimizu; Mitsune Tanimoto; Katsuyuki Kiura
Journal:  Mol Cancer Ther       Date:  2011-06-28       Impact factor: 6.261

4.  Expression of glutathione S-transferase pi (GST-pi) in human malignant ovarian tumors.

Authors:  T Satoh; M Nishida; H Tsunoda; T Kubo
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-06       Impact factor: 2.435

Review 5.  Recent approaches to improve the antitumor efficacy of temozolomide.

Authors:  Lucio Tentori; Grazia Graziani
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

6.  Multifactorial resistance to antineoplastic agents in drug-resistant P388 murine leukemia, Chinese hamster ovary, and human HeLa cells, with emphasis on the role of DNA topoisomerase II.

Authors:  A M Deffie; J P McPherson; R S Gupta; D W Hedley; G J Goldenberg
Journal:  Biochem Cell Biol       Date:  1992-05       Impact factor: 3.626

7.  miR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells.

Authors:  Lin Xia; Dexin Zhang; Rui Du; Yanglin Pan; Lina Zhao; Shiren Sun; Liu Hong; Jie Liu; Daiming Fan
Journal:  Int J Cancer       Date:  2008-07-15       Impact factor: 7.396

8.  The kinases MSK1 and MSK2 are required for epidermal growth factor-induced, but not tumor necrosis factor-induced, histone H3 Ser10 phosphorylation.

Authors:  Elizabeth A Duncan; Vasiliki Anest; Patricia Cogswell; Albert S Baldwin
Journal:  J Biol Chem       Date:  2006-03-03       Impact factor: 5.157

Review 9.  Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.

Authors:  A K Larsen; A Skladanowski
Journal:  Biochim Biophys Acta       Date:  1998-10-01

Review 10.  Novel RNA-based strategies for therapeutic gene silencing.

Authors:  Christopher R Sibley; Yiqi Seow; Matthew J A Wood
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

View more
  66 in total

Review 1.  Noncoding RNAs and pancreatic cancer.

Authors:  Juan-Fei Peng; Yan-Yan Zhuang; Feng-Ting Huang; Shi-Neng Zhang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

Review 2.  Epidrugs: targeting epigenetic marks in cancer treatment.

Authors:  Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal:  Epigenetics       Date:  2019-07-13       Impact factor: 4.528

3.  miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN.

Authors:  Xiaomin Yu; Yulong Chen; Ruiyun Tian; Jianxia Li; Hongyan Li; Teng Lv; Qin Yao
Journal:  Oncol Lett       Date:  2017-06-07       Impact factor: 2.967

4.  miR-300 regulates cellular radiosensitivity through targeting p53 and apaf1 in human lung cancer cells.

Authors:  Jinpeng He; Xiu Feng; Junrui Hua; Li Wei; Zhiwei Lu; Wenjun Wei; Hui Cai; Bing Wang; Wengui Shi; Nan Ding; He Li; Yanan Zhang; Jufang Wang
Journal:  Cell Cycle       Date:  2017-09-12       Impact factor: 4.534

5.  Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators.

Authors:  Marta Geretto; Alessandra Pulliero; Camillo Rosano; Dinara Zhabayeva; Rakhmet Bersimbaev; Alberto Izzotti
Journal:  Am J Cancer Res       Date:  2017-06-01       Impact factor: 6.166

Review 6.  Role of microRNAs on therapy resistance in Non-Hodgkin's lymphoma.

Authors:  Rong-Li Zheng; Yu-Jie Jiang; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

7.  miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.

Authors:  Wenjing Mu; Chaobo Hu; Haibin Zhang; Zengqiang Qu; Jin Cen; Zhixin Qiu; Chao Li; Haozhen Ren; Yixue Li; Xianghuo He; Xiaolei Shi; Lijian Hui
Journal:  Cell Res       Date:  2015-02-20       Impact factor: 25.617

8.  MicroRNA-542-3p Suppresses Tumor Cell Invasion via Targeting AKT Pathway in Human Astrocytoma.

Authors:  Junchao Cai; JingJing Zhao; Nu Zhang; Xiaonan Xu; Rong Li; Yang Yi; Lishan Fang; Le Zhang; Mengfeng Li; Jueheng Wu; Heng Zhang
Journal:  J Biol Chem       Date:  2015-08-18       Impact factor: 5.157

9.  MicroRNA-299-3p promotes the sensibility of lung cancer to doxorubicin through directly targeting ABCE1.

Authors:  Dawei Zheng; Yan Dai; Song Wang; Xiaoyu Xing
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

Review 10.  MicroRNAs as Mediators of Resistance Mechanisms to Small-Molecule Tyrosine Kinase Inhibitors in Solid Tumours.

Authors:  Michele Ghidini; Jens C Hahne; Melissa Frizziero; Gianluca Tomasello; Francesco Trevisani; Andrea Lampis; Rodolfo Passalacqua; Nicola Valeri
Journal:  Target Oncol       Date:  2018-08       Impact factor: 4.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.